Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833098 | 0.88 | MEN1 (0.73) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6813965 | 0.87 | MEN1 (0.72) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6818740 | 0.85 | RXFP1 (0.71) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6813720 | 0.83 | MEN1 (0.55) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6833263 | 0.81 | HDAC6 (0.51) | MEN1KMT2APOLBMAPTTP53 | |
| SCHEMBL6830650 | 0.81 | HSD17B10 (0.65) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6830367 | 0.79 | NPC1 (0.74) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6834032 | 0.79 | CHRNB2 (0.48) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6349859 | 0.79 | MAPT (0.76) | MEN1KMT2AHPGDMAPTALDH1A1 | |
| SCHEMBL6833066 | 0.78 | ALDH1A1 (0.59) | MEN1KMT2APOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | MEN1 4132/4885KMT2A 2853/4885POLB 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.